scispace - formally typeset
S

Sug Hyung Lee

Researcher at Catholic University of Korea

Publications -  463
Citations -  23933

Sug Hyung Lee is an academic researcher from Catholic University of Korea. The author has contributed to research in topics: Frameshift mutation & Germline mutation. The author has an hindex of 64, co-authored 454 publications receiving 21552 citations. Previous affiliations of Sug Hyung Lee include Chung-Ang University & The Catholic University of America.

Papers
More filters
Journal ArticleDOI

Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas.

TL;DR: It is demonstrated that aberrant promoter methylation of MGMT and p57 is an additional biological marker for predicting increased overall survival in patients with DLBCL.
Journal ArticleDOI

Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.

TL;DR: It is demonstrated that ATX is a key regulator of extracellular lysophosphatidic acid (LPA) that can act as survival factor, in addition to its mitogenic activity in mouse fibroblasts, and interventions to correct dysfunction in conditions of tumor cell growth and metastasis are suggested.
Journal ArticleDOI

Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers

TL;DR: The data indicate that N PM1 exon 12 is mutated in AMLs, but not in other common human cancers, and suggest that the NPM1 mutation may not play a role in the tumorigenesis of common solid cancers.
Journal ArticleDOI

ERBB2 kinase domain mutation in a gastric cancer metastasis.

TL;DR: The data suggest that ERBB2 kinase domain mutation occasionally occurs in metastatic Gastric carcinoma and might play a role in the metastatic process of some gastric carcinomas.
Journal ArticleDOI

Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma.

TL;DR: The results show that B2M mutation is common in MSU CRCs, which is one of the main targets for ICB treatment, suggesting that frequent B 2M mutation status should be reminded for MSu CRCs in patient selection of ICB.